<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220816055724N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-12-17</date_registration>
      <primary_sponsor>Arak University of Medical Sciences</primary_sponsor>
      <public_title>The Effect of Astragalus fasciculifolius and Phenytoin Cream on pain and episiotomy wound healing</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of Astragalus fasciculifolius and Phenytoin Cream on pain and episiotomy wound healing in primiparous women</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>120</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/65311</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study with a sample size of 120 people, to balance the number of samples allocated in each group, the participants will be randomly placed into three groups of 40 people (two intervention groups and one control group) by using the block permutation randomization. We need 20 blocks of 6 for 120 people. We select these blocks using random allocation software, which is capable of generating a random sequence using the blocking method, Blinding description: Astragalus fasciculifolius plant cream and placebo cream based on vaseline, prepared by a traditional medicine pharmacist and phenytoin cream prepared by Amin Pharmaceutical Company , at the traditional medicine research center, will be filled  in similar white tubes ( with a capacity of 60 cc) as named as A, B and C and will be available to the researcher to conduct research. The researcher, the participant, the outcome assessor , the results analyzer and the data safety and monitoring committee will not know the contents of the tubes until the end of the review and announcing the results.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: Pain severity. Condition 2: Wound healing.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1; Astragalus fasciculifolius Cream 10%: This herbal cream (Astragalus fasciculifolius plant), based on Vaseline and 10% active substance concentration,  will be made by a traditional medicine doctor in a traditional medicine laboratory. This cream is applied to the episiotomy area in the amount of 5 cc, every 8 hours, in the first 10 days after delivery. It is performed on the first day by the researcher and then on the following days by the mother (after training the mother). The mother will also receive routine treatment. Intervention 2: Intervention group 2; Phenytoin Cream 1%: Phenytoin cream 1% is produced by Amin Pharmaceutical Company. It is filled in a 60 mg white tube by a traditional medicine doctor for the purpose of blinding (like the tubes of other groups). This cream is applied to the episiotomy area in the amount of 5 cc, every 8 hours, in the first 10 days after delivery. It is performed on the first day by the researcher and then on the following days by the mother (after training the mother). The mother will also receive routine treatment. Intervention 3: Control group: Placebo Cream:  The Vaseline cream is filled in a 60 mg white tube by a traditional medicine doctor for the purpose of blinding (like the tubes of other groups).This cream is applied to the episiotomy area in the amount of 5 cc, every 8 hours, in the first 10 days after delivery. It is performed on the first day by the researcher and then on the following days by the mother (after training the mother). The mother will also receive routine treatment.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr Fereshteh Farzanazar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Mojtame Paiambarazam, Sardasht, Arak, Iran</address>
        <city>Arak</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>38481-7-6341</zip>
        <telephone>+98 86 3417 3520</telephone>
        <email>dr.faezanazar@arakmu.ac.ir</email>
        <affiliation>Arak University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Mehdi Salehi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Mojtame Paiambarazam, Sardasht, Arak, Iran</address>
        <city>Arak</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>38481-7-6341</zip>
        <telephone>+98 86 3417 3520</telephone>
        <email>dr.salehi@arakmu.ac.ir</email>
        <affiliation>Arak University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Normal pregnancy and delivery
primiparous
Age between 15-45
Having at least reading and writing literacy
Body mass index (after delivery) between 18.5-30 kilograms per square meter</inclusion_criteria>
      <agemin>15 years</agemin>
      <agemax>45 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Gestational age below 37 or above 42 weeks
Multiple pregnancy
Fetus Malpresentation
Suffering from diseases that interfere with wound healing such as: anemia, infection and perineum wounds, diabetes, High blood pressure, diseases of skin, heart, kidney, lung , coagulation disorder, immunodeficiency, hemophilia, disorder of connective tissue, depression, malnutrition, mental illnesses, cancer)
Using drugs effective on wound healing such as: anticoagulants, antidepressants, antiepileptics), glucocorticoids, immune system suppressors, antibiotics, narcotics and psychotropic drugs,  chemotherapy
Rupture of  Amionitic membran more than 18 hours
Instrumental vaginal delivery or non-medial or lateral episiotomy incision
Non spontaneous removal of the placenta
History of previous injury or surgery or visible lesions in the perineum such as: genital warts, hemorrhoids
Alcohol drinking or smoking
Persistent constipation (according to the mother statement )</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G89.18</hc_code>
      <hc_code>O90.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other acute post procedural pain</hc_keyword>
      <hc_keyword>Disruption of peritoneal obstetric wound</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1; Astragalus fasciculifolius Cream 10%: This herbal cream (Astragalus fasciculifolius plant), based on Vaseline and 10% active substance concentration,  will be made by a traditional medicine doctor in a traditional medicine laboratory. This cream is applied to the episiotomy area in the amount of 5 cc, every 8 hours, in the first 10 days after delivery. It is performed on the first day by the researcher and then on the following days by the mother (after training the mother). The mother will also receive routine treatment.</i_keyword>
      <i_keyword>Intervention group 2; Phenytoin Cream 1%: Phenytoin cream 1% is produced by Amin Pharmaceutical Company. It is filled in a 60 mg white tube by a traditional medicine doctor for the purpose of blinding (like the tubes of other groups). This cream is applied to the episiotomy area in the amount of 5 cc, every 8 hours, in the first 10 days after delivery. It is performed on the first day by the researcher and then on the following days by the mother (after training the mother). The mother will also receive routine treatment.</i_keyword>
      <i_keyword>Control group: Placebo Cream:  The Vaseline cream is filled in a 60 mg white tube by a traditional medicine doctor for the purpose of blinding (like the tubes of other groups).This cream is applied to the episiotomy area in the amount of 5 cc, every 8 hours, in the first 10 days after delivery. It is performed on the first day by the researcher and then on the following days by the mother (after training the mother). The mother will also receive routine treatment.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain. Timepoint: Days1, 5 and 10 after delivery. Method of measurement: Visual analog scale (VAS).</prim_outcome>
      <prim_outcome>Episiotomy wound healing. Timepoint: Days1, 5 and 10 after delivery. Method of measurement: Reeda Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Drug side effect. Timepoint: Days 5 and 10 after delivery. Method of measurement: questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Arak University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-06-26</approval_date>
        <contact_name>Ethics Committee of Arak University of Medical Sciences</contact_name>
        <contact_address>Arak University Of Medical Science, Almalhoda Avenue, Arak, Iran Arak Markazi Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
